Table 2.

Performance of optimized classifiers during first 16 months of implementation in GenoVA Study trial

Metric	AFib	CAD	T2D	BrCa	CRCa	PrCa
Total
Screened participants	1,077	1,077	1,077	259	1,077	818
Mispredicted as negative*	13	20	15	2	2	4
NPV-RW	98.8%	98.2%	98.6%	99.2%	99.9%	99.5%
Male
Screened participants	818	818	818	-	818	818
Mispredicted as negative	11	19	13	-	1	4
NPV-RW	98.7%	97.7%	98.4%	-	99.9%	99.5%
Female
Screened participants	259	259	259	259	259	-
Mispredicted as negative	2	1	2	2	1	-
NPV-RW	99.2%	99.6%	99.2%	99,2%	99.6%	-
Non-Hispanic White
Screened participants	592	592	592	186	592	406
Mispredicted as negative	8	10	4	1	1	2
NPV-RW	98.7%	98.3%	99.3%	99.5%	99.8%	99.5%
Non-Hispanic Other Races
Screened participants	380	380	380	65	380	315
Mispredicted as negative	3	7	7	1	1	1
NPV-RW	99.2%	98.2%	98.2%	98.5%	99.7%	99.7%
Hispanic White
Screened participants	66	66	66	1	66	65
Mispredicted as negative	2	2	2	0	0	1
NPV-RW	97.1%	97.1%	97.1%	100%	100%	98.5%
Hispanic Other Races
Screened participants	39	39	39	7	39	32
Mispredicted as negative	0	1	2	0	0	0
NPV-RW	100%	97.5%	95.1%	100%	100%	100%

^*54 participants self-reported a diagnosis of exactly 1 disease, and 2 participants self-reported diagnoses for 2 separate diseases each.